Aim: To investigate the effect of recombined human glucagon-like peptide 1 (rhGLP-1 ) on the secretion and expression of amylin in Goto-Kakizaki (GK) rats. Methods: The GK rats were treated with rhGLP-1 (7-36) 56 and 133 µg·kg -1 subcutaneously for 12 weeks. The fasting and post-prandial blood glucose levels were measured. The plasma amylin concentration was measured by ELISA. The transcription levels of amylin and insulin mRNA were evaluated by fluorescent-quantitative-PCR. Immunohistochemistry was utilized to detect the amylin protein.
Introduction
Type 2 diabetes is a chronic metabolic disease, which is characterized by fasting hyperglycemia that worsens as the disease progresses. Data from the UK Prospective Diabetes Study (UK-PDS) have shown that an almost inevitable progressive β-cell failure occurs despite the use of various therapies aimed at ameliorating hyperglycemia [1] . Several mechanisms may contribute to the progressive β-cell failure in type 2 diabetes, including loss of β-cell mass, β-cell exhaustion, and the cytotoxic effects of elevated glucose and lipid levels. A growing body of evidence suggests that islet amyloid deposits may play an important role in the loss of β-cells and the progressive decline in insulin secretion [2] . Westermark et al [3] identified the major component of islet amyloid as a 37 amino acid peptide and named it amylin or islet amyloid polypeptide. In type 2 diabetes, this peptide aggregates to form amyloid fibrils that are toxic to β-cells [4] . The mechanism responsible for islet amyloid formation in type 2 diabetes is still unclear, but it appears that an increase in the secretion and expression of amylin [5] [6] can result in its onset.
Amylin is colocalized with insulin in the isle β-cells and is cosecreted with insulin in response to β-cell stimulation by both glucose and non-glucose secretagogues agents, such as arginine [7] . Therefore, therapies that alter endogenous insulin secretion are likely to cause parallel changes in amylin secretion. In fact, previous studies have suggested that sulfonylurea therapy increases the post-prandial amylin concentration, but not so in insulin therapy [8] . These changes in turn may influence the rate of the formation of islet amyloids, which may be disadvantageous in the long term.
Glucagon-like peptide 1 (GLP-1) is an incretin hormone secreted from the intestinal L-cell in response to meal ingestion. In the pancreas, GLP-1 stimulates meal-induced insulin secretion in a glucose-dependent manner, dramatically lowering post-prandial glucose levels [9, 10] . More recently, the direct effects on β-cell growth and survival have been identified, with the GLP-1-stimulated proliferation and differentiation of new β-cells leading to increased β-cell mass [11] [12] [13] . Furthermore, GLP-1 delays gastric emptying. These observations support GLP-1 as a novel candidate for the treatment of type 2 diabetes. However, it is not clear whether GLP-1 would elevate the amylin concentration, like sulfonylurea, which would weaken its effectiveness on diabetes therapy.
The Goto-Kakizaki (GK) rat has been used as an animal model for type 2 diabetes. This animal is a non-obese, spontaneously-diabetic rat produced by selective inbreeding of Wistar rats with the highest glucose values during oral glucose tolerance tests. In vitro investigations of the perfused pancreas of GK rats as well as of diabetic animals in vivo have revealed an impairment of the glucose-induced release of insulin. Further, histological studies have shown an irregular shape of some, but not all, islets in GK rats aged 3 months or older [14, 15] . The purpose of this study was to examine the effect of the GLP-1 derivative, recombined human GLP-1 [rhGLP-1 (7-36)], on the fasting and post-prandial amylin concentrations and islet amylin and insulin mRNA levels to determine whether amylin secretion would be altered in a way that might affect the action of insulinotropic drugs in GK rats.
Materials and methods
Rats Male spontaneously-diabetic GK rats (34 weeks old) and non-diabetic Wistar rats were supplied by and bred at Shanghai Slac Laboratory Animals. The rats were housed under controlled conditions of constant temperature and humidity.
Experimental protocol There were 4 groups in the experiment. The Wistar rats were used as the normal control group. The GK rats were divided randomly into 3 groups. The first group, which was given saline solution, served as the vehicle-treated group; the other two groups were given rhGLP-1 (7-36), 56 µg·kg -1 for the GK/GL (given GLP-1 low dose) group and 133 µg·kg -1 for the GK/GH (given GLP-1 high dose) group by subcutaneous injection ter in die (tid) for 12 weeks, respectively (provided by Shanghai Huayi Biolab, Shanghai, China).
Measurement of blood glucose
In each rat group, the body weight and fasting blood glucose (overnight fasting for 18 h) were monitored at 0, 1, 3, 5, 7, and 11 weeks of the treatment with rhGLP-1 (7-36). In the 11th week, the postprandial blood glucose level was measured at 30 and 60 min after feeding by the Roche Glucotrend-2 glucometer (Lewes, East Sussex, UK) [16] . Intraperitoneal glucose tolerance test [17] and the measurement of plasma amylin In the 12th week of treatment following overnight fasting for 18 h, the rats were subjected to an intraperitoneal glucose tolerance test (IPGTT). A glucose solution (20%, 1 g·kg -1 body weight) was injected intraperitoneally, and blood samples were collected from the ophthalmic vein at 0, 15, 30, 60, 120, and 180 min after the glucose injection. The blood glucose levels were measured using the Roche Glucotrend-2 glucometer [16] . The samples were centrifuged at 4 °C. The plasma samples were stored at -20 °C until the assay. Plasma amylin was determined using an ELISA kit (Uscn Life Science and Technology, Missouri City, TX, USA) based on the standard curve [18] . Directly after the glucose tolerance test, the rats were killed by dislocation of the cervical vertebra, and the pancreatic tissues were taken for further studies.
Histological examination The rat pancreata were fixed in 10% neutral buffered formalin and embedded in paraffin. Each pancreatic block was serially sectioned (6 µm) to avoid any bias from regional changes in islet distribution and islet cell composition; the sections were then mounted on slides. Then 10 sections were randomly chosen at a fixed interval throughout the block. Half the sections were stained with hematoxylin-eosin (HE) for light microscopy.
Examination of islet number In total, 45 sections stained with HE were chosen from each group. The number of islets in each section was counted in 10 random, non-overlapping fields under light microscopy (magnification ×250).
Immunohistochemistry For the immunohistochemical demonstration of amylin, the streptavidin-biotin-peroxidase complex (SABC) technique was employed [19, 20] . After routine deparaffinization, rehydration, and blocking of endogenous peroxidase activity, the sections underwent antigen retrieval. Subsequently, the sections were incubated with a rabbit antiserum against rat amylin (AssayPro, Winfield, MO, USA) antibody diluted at 1:100 in phosphate-buffered saline, followed by incubation with biotinylated antirabbit immunoglobulin G (IgG; Boster, Wuhan, China) and SABC reagent incubation. Staining was visualized by incubation with 3,3´-diaminobenzidine-tetrahydrochloride (Boster, China). The sections were counterstained with hematoxylin, mounted in a neutral gum, and examined under light microscopy. For the melting curve analysis after the PCR amplification, the fluorescence signal was measured at the end of the elongation phase at 84 °C. The obtained mRNA level was expressed relative to that of the GAPDH (internal control) PCR product amplified from the same sample (sample PCR product/GAPDH PCR product).
Statistical analysis Quantitative variables were expressed as mean±SD. One-way ANOVA was used for the analysis. If any significant change was found, post-hoc comparisons were performed using Fisher's PLSD (Protected least significant difference). The ratio of amylin/insulin mRNA was assessed by the Mann-Whitney U-test. P<0.05 was considered significant.
Results
Fasting and post-prandial blood glucose Both the fasting and post-prandial blood glucose levels were significantly higher in the untreated GK rats than the Wistar rats (P<0.01; Table 1 ). The GK/GL and GK/GH rats treated with 56 and 133 µg·kg -1 rhGLP-1 (7-36), showed significantly lower blood glucose levels at 30 and 60 min after feeding compared with the untreated GK group (P<0.05; Table 1 ). There was no significant difference in the fasting blood glucose level (P>0.05).
Levels of blood glucose in IPGTT Before the glucose administration, the fasting blood glucose levels were significantly higher in the GK rats than in the Wistar rats (P<0.01; Table 2 ). Following the intraperitoneal glucose injection in the GK rats, the blood glucose level at 15 min had risen to a greater extent than in the Wistar rats and continued to do so for the remainder of the experiment. The GK/GL and GK/GH rats treated with 56 and 133 µg·kg -1 rhGLP-1 (7-36) showed significantly lower blood glucose levels after glucose loading compared with the untreated GK group (P<0.05; Table 2 ). There was no significant difference at the fasting state (P>0.05).
Amylin concentrations in plasma The plasma amylin levels were lower in the untreated GK rats than in the Wistar controls, both during basal conditions (P<0.05) and after the glucose administration (P<0.01; Figure 1 ). The basal plasma amylin levels in the GK/GL and GK/GH rats showed a descending trend compared to those in the untreated GK rats (P>0.05). In response to the intraperitoneal glucose administration, the plasma amylin levels of the GK/GH rats displayed a marked increase at 30 min after the injection compared with the untreated GK rats (P<0.05; Figure 1 ), whereas the increase in the GK/GL rats did not reach significance (P=0.09). In the Wistar control rats, the levels had increased significantly at 30 min, then remained at a similar level at 60 min (P<0.05; Figure 1 ).
Histology and number of islets
In contrast to the findings in the Wistar control rats (Figure 2A ), the islets of the GK rats usually had a very irregular shape, and the islets sometimes had a broken appearance ( Figure 2B ). The boundary between the islets and exocrine pancreas was irregular. Some islet cells seemed degenerate and swollen. In many sections, a few islets were also found that displayed a rounded, clear-cut shape like the normal ones seen in the Wistar control rats. The number of islets was markedly decreased in the GK rats compared to the Wistar control rats (P<0.01; Figure 3 ). No differences were found in the number of islets between the GK/GL or GK/GH rats and untreated GK rats. However, the GK/GL and GK/GH rats showed slight histological amelioration ( Figure 2C,2D) .
Immunohistochemistry finding Immunostaining for amylin showed conclusive positivity in many cells of the pancreatic islets in the Wistar rats ( Figure 4A ). The exocrine pancreata were completely negative for amylin. Few scattered cells were immunopositive for amylin in the untreated GK rats ( Figure 4B ). However, the GK/GL and GK/GH rats showed more rich amylin-positive cells compared to the untreated GK rats ( Figure 4C,4D) , although the positivelystained cells were still less than those of the Wistar rats. Amylin and insulin mRNA levels In the untreated GK rats, the levels of amylin and insulin mRNA were significantly reduced (P<0.01). However, there was a more pronounced reduction in the levels of insulin mRNA than amylin mRNA. The levels of insulin mRNA in the untreated GK rats was 24% of that of the Wistar controls, whereas the levels of amylin mRNA in untreated GK rats was 59% of that of the Wistar controls. The GK/GL and GK/GH rats both showed marked increases of amylin and insulin mRNA compared with the untreated GK rats ( Figure 5 ).
The amylin to insulin mRNA ratio of the untreated GK rats was significantly higher than that of the Wistar rats (P<0.05, 164.51%±43.86% vs 63.25%±13.76%). The ratio in the GK/GL and GK/GH rats was decreased with the rhGLP-1 (7-36) treatment compared to the untreated GK rats (P<0.05; Figure 6 ).
Discussion
Type 2 diabetes is characterized by insulin resistance and progressive β-cell dysfunction leading to insulin deficiency [21] . The importance of aggressive glucose-lowering therapy to prevent late diabetes complications in type 2 diabetes has been convincingly established [22, 23] . However, the UK-PDS also demonstrated that the antidiabetic treatment used failed to maintain acceptable glycemic control in the vast majority of patients, emphasizing the need for more effective antidiabetic agents. Treatment failure was attributed to progressive β-cell exhaustion in type 2 diabetes. Recently, amylin has been suggested to be responsible for β-cell failure during the progression of type 2 diabetes [1] . GLP-1 has been shown to acutely reduce plasma glucose levels by increasing insulin release and synthesis, inhibiting glucagon release, and decreasing gastric emptying and appetite. Long-term beneficial effects have also been shown in human and rodent models [24, 25] . These findings indicate that GLP-1 is potentially a very attractive agent for treating type 2 diabetes. In the present study, we investigated the effects of 12 weeks of treatment with rhGLP-1 (7-36) on blood glucose and hormone profiles. Treatment with 56 and 133 µg·kg -1 RhGLP-1 (7-36) treatment markedly improved the glucose tolerance and reduced the blood glucose level of GK rats after glucose loading , whereas no difference was observed in the fasting glucose level. The result was possibly attributed to the short half-life of GLP-1 . GLP-1 (7-36) was rapidly degraded by the ubiquitous enzyme dipeptidyl peptidase IV [26] . This enzyme, which is present in the bloodstream and on cell membranes, cleaves the GLP-1 (7-36) peptide to yield the inactive GLP-1 (9-36) form. Therefore, the subcutaneous injection tid treatment of the GLP-1 tide is probably insufficient in ensuring the effective plasma concentration of the GLP-1 (7-36) peptide, which results in the loss of glycemic control and decreased glucose toxicity. As we known, amyloid deposition, which is composed of amylin, is a predominant factor resulting in β-cell failure in type 2 diabetes [1] . In our study, few scattered cells were immunopositive for amylin in the pancreatic islets of the untreated GK rats compared to the Wistar rats. This finding may indicate that the amylin content decreased in the islet secretory cells of the GK rats. However, the GLP-1 (7-36) treatment caused more abundant amylin-positive cells compared to the untreated GK rats. That is, GLP-1 (7-36) increased the amylin content. We then tested the plasma amylin concentration after the glucose administration. The result was consistent with the change of content. GLP-1 (7-36) elevated the levels of plasma amylin in response to the intraperitoneal glucose administration. A limitation of our study was that we only measured 3 time points after the intraperitoneal glucose administration due to the low plasma sample amount. Nevertheless, the parallel relationship between the amylin content and amylin secretion was clear and was consistent with previous studies [27] . However, the increase in the production and secretion of amylin may be an important contributor to amyloid fibril formation. That is, GLP-1 (7-36) may promote the formation of amyloid deposition, but is this true?
To answer this question, we designed the protocol to investigate the effect of GLP-1 (7-36) on the amylin mRNA level. The present study, using FQ-PCR, examined the changes in the amylin and insulin mRNA levels in GLP-1 (7-36)-treated GK rats. In the untreated GK rats, the quantitative findings revealed a marked reduction of the amylin and insulin mRNA in the islets, whereas the level of amylin mRNA was less reduced than that of insulin mRNA. Therefore, the ratio of amylin to insulin mRNA was sharply increased in the untreated GK rats compared to the Wistar rats, which was almost 2-fold higher. It has been proposed that the amylin/ insulin ratio may be worth investigating rather than the absolute amylin mRNA level. It is not clear whether the increase in the amylin/insulin mRNA ratio in GK rats is a primary feature or is secondary to hyperglycemia. Interestingly, hyperglycemia results in the hypersecretion of amylin relative to that of insulin as well as increasing the amylin /insulin ratio in insulin-resistant rats. Furthermore, it was recently shown that the level of amylin mRNA increased more than that of insulin mRNA in insulinoma cell line, INS-1 cells, cultured in a medium containing 100 µmol/L isobutylmethylxanthine [28] . Thus it is not inconceivable that the expression of amylin may be more sensitive to hyperglycemia and peripheral insulin resistance than that of insulin under certain conditions. An increased ratio of amylin/insulin expression seems to be a marker for insulin cell dysfunction under certain conditions.
In our research, the treatment with GLP-1 (7-36) significantly increased the amylin and insulin mRNA levels, but markedly decreased the ratio of amylin/insulin mRNA in the GK rats. This result further confirms that GLP-1 (7-36) stimulated an augmentation of the secretion and expression of amylin in islet cells, which was consistent with other findings. An increase of insulin protein expression was also certified in the GK rats treated with GLP-1 (7-36) by immunohistochemistry [29] . Therefore, it is not clear whether the augmentation resulted from the either the direct effect of GLP-1 (7-36) on stimulating amylin or the secondary effect of GLP-1 (7-36) on stimulating insulin. Our other interest was in exploring the influence of GLP-1 (7-36) treatment on the decreased the ratio of amylin/insulin mRNA. The result contributes notably to the clinical treatment of GLP-1 (7-36) in type 2 diabetes, including pathophysiological changes. Putative mechanisms promote amylin gene expression separate from insulin gene expression. However, the effect of GLP-1 (7-36) on the pathways and sites of amylin and insulin gene expression regulation require further study.
